SCHEMBL5465350

SCHEMBL5465350

O=C(Nc1nccc(-c2ccc3ccccc3c2)n1)c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 10/20 0.68
▸ ADORA1 P30542 1/20 0.56
▸ DKK1 O94907 1/20 0.54
▸ GSK3B P49841 1/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ ABL1 P00519 1/20 0.54
▸ PRKCG P05129 1/20 0.54
▸ PRKCB P05771 1/20 0.54
▸ PDGFRB P09619 1/20 0.54
▸ BCR P11274 1/20 0.54
▸ SRC P12931 1/20 0.54
▸ PDGFRA P16234 1/20 0.54
▸ PRKCA P17252 1/20 0.54
▸ PRKCH P24723 1/20 0.54
▸ PRKCI P41743 1/20 0.54
▸ PRKCE Q02156 1/20 0.54
▸ PRKCQ Q04759 1/20 0.54
▸ PRKCZ Q05513 1/20 0.54
▸ PRKCD Q05655 1/20 0.54
▸ PRKD1 Q15139 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465449 0.88 PIK3CA (0.58) SIRT2ADORA1PRKD3ABL1PRKCG
SCHEMBL5470852 0.86 ADORA1 (0.69) ADORA1GSK3BPRKD3ABL1PRKCG
SCHEMBL5472823 0.83 ADORA1 (0.57) ADORA1GSK3BPRKD3ABL1PRKCG
SCHEMBL5473232 0.83 DYRK1A (0.63) ADORA1PRKD3ABL1PRKCGPRKCB
SCHEMBL5472470 0.83 ADORA3 (0.65) ADORA1PRKD3ABL1PRKCGPRKCB
SCHEMBL5472976 0.82 PIK3CA (0.59) ADORA1GSK3BJAK2CAMK2D
SCHEMBL5462697 0.82 ALDH1A1 (0.58) SIRT2ADORA1GSK3BPRKD3ABL1
SCHEMBL5466020 0.82 RAB9A (0.67) SIRT2DKK1GSK3BABL1PDGFRB
SCHEMBL5465855 0.82 HDAC1 (0.67) ADORA1ABL1BCRPRKCAJAK2
SCHEMBL5472892 0.80 JAK2 (0.76) ADORA1JAK2CAMK2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 — — US disclosed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099938-A1 Antistress drug and medical use thereof NPSR1, MC2R, SRR SIRT2 1809/4885ADORA1 134/4885DKK1 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback